Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Lung Neoplasms × trilaciclib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 2 Expanded_access 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Lung Neoplasms 1

Interventions

trilaciclib 1 taletrectinib 1 lazertinib 1 dabrafenib 1 capmatinib 1 brigatinib 1 Suspensions 1 Powders 1 Paclitaxel 1 BID protein, human 1 AMG 757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

G1 Therapeutics, Inc.

Approved for marketing

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡